Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05479981 · ClinicalTrials.gov registry record · Phase 2
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
A Phase 2 study of Nervous System Diseases and Neuromuscular Diseases, sponsored by Avidity Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 8
- Study locations
NCT05479981: Completed Phase 2 study of Nervous System Diseases and Neuromuscular Diseases, sponsored by Avidity Biosciences.
NCT05479981 is a Phase 2 study of Nervous System Diseases and Neuromuscular Diseases that has completed, run by Avidity Biosciences. The registered enrollment target is 37 participants, below the 322-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (89% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05479981, a Phase 2 study of Nervous System Diseases and Neuromuscular Diseases, has completed, sponsored by Avidity Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 8
- Study locations
Study Summary
AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AOC 1001
Study Locations (8)
California
- University of California Los Angeles - Los Angeles
- Stanford University - Palo Alto
Colorado
- University of Colorado - Denver
Florida
- University of Florida - Gainesville
Kansas
- Kansas University Medical Center - Kansas City
New York
- University of Rochester Medical Center - Rochester
Ohio
- Ohio State University - Columbus
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2022-08-04 |
| Est. Completion | 2025-09-10 |
| Phase | Phase 2 |
What the finished NCT05479981 record still lists
NCT05479981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 322-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (89% lower).
The record links to 10 conditions, with Nervous System Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05479981 lists 8 locations in 7 states (California, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT05479981 about?
NCT05479981 is a clinical study titled "Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients". AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients
What is the current status of trial NCT05479981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2022-08-04. Estimated completion is 2025-09-10.
What conditions does trial NCT05479981 study?
This clinical trial studies the following conditions: Nervous System Diseases, Neuromuscular Diseases, Muscular Dystrophies, Musculoskeletal Diseases, Myotonic Dystrophy.
What interventions are being tested in trial NCT05479981?
The interventions under investigation include: Placebo (DRUG), AOC 1001 (DRUG).
Who is sponsoring clinical trial NCT05479981?
This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05479981 being conducted?
This trial has 8 study locations across California, Colorado, Florida, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nervous System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05479981's enrollment target sits among peer trials
37 20th of 23 higher than 4 of 23 other Nervous System Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nervous System Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
RECRUITING
-
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
RECRUITING · NA
-
Rett Syndrome Registry
RECRUITING
-
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI